Bavituximab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Bavituximab" in English language version.

refsWebsite

Global rank English rank

2^nd place

2^nd place

4^th place

4^th place

2semanticscholar.org

11^th place

8^th place

274^th place

309^th place

low place

7,595^th place

572^nd place

436^th place

1peregrineinc.com

low place

low place

1web.archive.org

1^st place

1^st place

1clinicaltrials.gov

5,225^th place

4,062^nd place

low place

low place

low place

low place

1biopharmadive.com

low place

low place

biopharmadive.com

Elvidge S (February 13, 2018). "Avid sells off cancer assets, transitioning to CDMO". BioPharma Dive.

biospace.com

"Peregrine Pharmaceuticals' Bavituximab Shows Potential Activity Against Avian Flu In Initial Testing". 24 May 2006. Retrieved 26 April 2020.

clinicaltrials.gov

Clinical trial number NCT01999673 for "Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer (SUNRISE) " at ClinicalTrials.gov

doi.org

Mahoney KM, Rennert PD, Freeman GJ (August 2015). "Combination cancer immunotherapy and new immunomodulatory targets". Nature Reviews. Drug Discovery. 14 (8): 561–584. doi:10.1038/nrd4591. PMID 26228759. S2CID 2220735.
Ahn J, Flamm SL (August 2011). "Hepatitis C therapy: other players in the game". Clinics in Liver Disease. 15 (3): 641–656. doi:10.1016/j.cld.2011.05.008. PMID 21867942.
Soares MM, King SW, Thorpe PE (December 2008). "Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases". Nature Medicine. 14 (12): 1357–1362. doi:10.1038/nm.1885. PMC 2597367. PMID 19029986.
Tse MT, King SW, Thorpe PE (January 2009). "Exposed target for broad-spectrum antivirals". Nature Reviews Drug Discovery. 8 (1): 19. doi:10.1038/nrd2788. S2CID 19531326.

nih.gov

pubmed.ncbi.nlm.nih.gov

Mahoney KM, Rennert PD, Freeman GJ (August 2015). "Combination cancer immunotherapy and new immunomodulatory targets". Nature Reviews. Drug Discovery. 14 (8): 561–584. doi:10.1038/nrd4591. PMID 26228759. S2CID 2220735.
Ahn J, Flamm SL (August 2011). "Hepatitis C therapy: other players in the game". Clinics in Liver Disease. 15 (3): 641–656. doi:10.1016/j.cld.2011.05.008. PMID 21867942.
Soares MM, King SW, Thorpe PE (December 2008). "Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases". Nature Medicine. 14 (12): 1357–1362. doi:10.1038/nm.1885. PMC 2597367. PMID 19029986.

ncbi.nlm.nih.gov

Soares MM, King SW, Thorpe PE (December 2008). "Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases". Nature Medicine. 14 (12): 1357–1362. doi:10.1038/nm.1885. PMC 2597367. PMID 19029986.

ocbj.com

Brennan PJ (December 26, 2017). "Peregrine Names CEO, to Change Name". Orange County Business Journal.

onclive.com

Inman S (February 26, 2016). "Peregrine Stops Phase III Trial of Bavituximab in NSCLC". OncLive.

peregrineinc.com

ir.peregrineinc.com

Peregrine press release: Peregrine Pharmaceuticals Licenses Additional Intellectual Property for Its Anti-Phospholipid Therapy Platform Technology Archived 2016-02-16 at the Wayback Machine. July 6, 2004

sec.gov

Peregrine's Annual Report for the fiscal year ended April 30, 2015

semanticscholar.org

api.semanticscholar.org

Mahoney KM, Rennert PD, Freeman GJ (August 2015). "Combination cancer immunotherapy and new immunomodulatory targets". Nature Reviews. Drug Discovery. 14 (8): 561–584. doi:10.1038/nrd4591. PMID 26228759. S2CID 2220735.
Tse MT, King SW, Thorpe PE (January 2009). "Exposed target for broad-spectrum antivirals". Nature Reviews Drug Discovery. 8 (1): 19. doi:10.1038/nrd2788. S2CID 19531326.

springer.com

adisinsight.springer.com

"Bavituximab - Avid Bioservices". Adis Insight. Springer Nature Switzerland AG.

web.archive.org

Peregrine press release: Peregrine Pharmaceuticals Licenses Additional Intellectual Property for Its Anti-Phospholipid Therapy Platform Technology Archived 2016-02-16 at the Wayback Machine. July 6, 2004